No abstract available
Keywords:
efficacy; eltrombopag; immune thrombocytopenia; rituximab; safety.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzoates / administration & dosage
-
Benzoates / adverse effects
-
Benzoates / therapeutic use*
-
Clinical Trials, Phase III as Topic
-
Humans
-
Hydrazines / administration & dosage
-
Hydrazines / adverse effects
-
Hydrazines / therapeutic use*
-
Molecular Targeted Therapy
-
Purpura, Thrombocytopenic, Idiopathic / diagnosis
-
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
-
Purpura, Thrombocytopenic, Idiopathic / etiology
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Receptors, Thrombopoietin / antagonists & inhibitors
-
Retreatment
-
Rituximab / drug effects
-
Treatment Outcome
Substances
-
Benzoates
-
Hydrazines
-
Pyrazoles
-
Receptors, Thrombopoietin
-
Rituximab
-
eltrombopag